" class="no-js "lang="en-US"> David Dornan - Medtech Alert
Thursday, December 05, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Dornan

David Dornan

About David Dornan

Leader in cancer biology with impactful scientific publications and extensive experience spanning across basic cancer cell biology, immuno-oncology, and translational research programs in target discovery & validation, predictive and pharmacodynamic biomarkers, toxicology, and regulatory filings applied to biologics and small molecule targets across various technology platforms.

Related Story

Appointments

 Elevation Oncology Appoints David Dornan

Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer

March 14 2022

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines […]